1
Douglas J Allen, Kirk W Johnson, Robert S Nevin: Hydrophilic polyurethane membranes for electrochemical glucose sensors. Eli Lilly and Company, Woodward Emhardt Naughton Moriarty & McNett, June 21, 1994: US05322063 (810 worldwide citation)

Homogeneous membranes permeable to oxygen and glucose composed of hydrophilic polyurethanes that are capable of absorbing from 10 to 50% of their dry weight of water. Variations in the composition of the hydrophilic polyurethanes make possible the fabrication of membranes in which the ratios of the ...


2
Douglas J Allen, Robert S Nevin: Acrylic copolymer membranes for biosensors. Eli Lilly and Company, Woodard Emhardt Naughton Moriarty & McNett, February 8, 1994: US05284140 (388 worldwide citation)

Homogeneous membranes are disclosed which are composed of acrylic copolymers and are capable of absorbing 10% to 50% of their dry weight of water. The copolymers include a hydrophilic component which comprises acrylic esters having a poly(ethylene oxide) substituent as part of the alcohol moiety. Th ...


3
Douglas J Allen, Robert S Nevin: Acrylic copolymer membranes for biosensors. Eli Lilly and Company, Woodard Emhardt Naughton Moriarty & McNett, December 19, 1995: US05476094 (94 worldwide citation)

Homogeneous membranes are disclosed which are composed of acrylic copolymers and are capable of absorbing 10% to 50% of their dry weight of water. The copolymers include a hydrophilic component which comprises acrylic esters having a poly(ethylene oxide) substituent as part of the alcohol moiety. Th ...


4
Douglas J Allen, Kurt D Dekemper, Thomas H Ferguson, Stuart J Garvin, Linda C Murray, Norman D Brooks, Charles A Bunnell, Snehlata S Mascarenhas, Sharon L Shinkle, Barry A Hendriksen, David E Tupper, Manuel V Sanchez Felix: 2-methyl-thieno-benzodiazepine formulation. Eli Lilly and Company, Nelsen L Lentz, Arleen Palmberg, September 9, 2003: US06617321 (3 worldwide citation)

The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation or olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.


5
Douglas J Allen, Kurt D Dekemper, Thomas H Ferguson, Stuart J Garvin, Linda C Murray, Norman D Brooks, Charles A Bunnell, Snehlata S Mascarenhas, Sharon L Shinkle, Barry A Hendriksen, David E Tupper, Manuel V Sanchez Felix: 2-methyl-thieno-benzodiazepine formulation. Eli Lilly and Company, Nelson L Lentz, December 4, 2007: US07303764 (2 worldwide citation)

The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.


6
Douglas J Allen, Kurt D Dekemper, Thomas H Ferguson, Stuart J Garvin, Linda C Murray, Norman D Brooks, Charles A Bunnell, Snehlata S Mascarenhas, Sharon L Shinkle, Barry A Hendriksen, David E Tupper, Manuel V Sanchez Felix: 2-methyl-thieno-benzodiazepine formulation. Eli Lilly And Company, May 20, 2004: US20040097489-A1

The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.


7
Douglas J Allen, Kurt D Dekemper, Thomas H Ferguson, Stuart J Garvin, Linda C Murray, Norman D Brooks, Charles A Bunnell, Snehlata S Mascarenhas, Sharon L Shinkle, Barry A Hendriksen, David E Tupper, Manuel V Sanchez Felix: 2-methyl-thieno-benzodiazepine formulation. Eli Lilly And Company, February 6, 2003: US20030027816-A1

The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.